These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21640689)

  • 41. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
    Shlyakhto E
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S13-8. PubMed ID: 18093409
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group.
    Gradman AH; Gray J; Maggiacomo F; Punzi H; White WB
    Clin Ther; 1999 Mar; 21(3):442-53. PubMed ID: 10321414
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress.
    Frank H; Schobel HP; Vitkowsky J; Schmieder RE; Heusser K
    Kidney Int; 2003 Feb; 63(2):617-23. PubMed ID: 12631126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
    Brodsky S; Gurbanov K; Abassi Z; Hoffman A; Ruffolo RR; Feuerstein GZ; Winaver J
    Hypertension; 1998 Oct; 32(4):746-52. PubMed ID: 9774374
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men.
    Price DA; De'Oliveira JM; Fisher ND; Hollenberg NK
    Hypertension; 1997 Aug; 30(2 Pt 1):240-6. PubMed ID: 9260987
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.
    Martin DE; DeCherney GS; Ilson BE; Jones BA; Boike SC; Freed MI; Jorkasky DK
    J Clin Pharmacol; 1997 Feb; 37(2):155-9. PubMed ID: 9055142
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.
    Hollenberg NK
    Curr Hypertens Rep; 2001 Sep; 3 Suppl 1():S25-8. PubMed ID: 11580885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The renal profile of eprosartan.
    Sica DA; Hollenberg NK
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):86S-94S. PubMed ID: 10213527
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study.
    Petrella RJ; Shlyakhto E; Konradi AO; Berrou JP; Sedefdjian A; Pathak A;
    J Clin Hypertens (Greenwich); 2012 Feb; 14(2):78-84. PubMed ID: 22277139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Elevation pressure in morning hours in patients with essential hypertension: effect therapy with eprosartan for leading stress tests].
    Shevchenko OP; Praskurnichiĭ EA; Makarova SV; Samartsev GA; Lapina EIa
    Kardiologiia; 2004; 44(3):58-63. PubMed ID: 15489829
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension.
    Stokes GS; Barin ES; Gilfillan KL
    Hypertension; 2003 Feb; 41(2):297-301. PubMed ID: 12574098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eprosartan: a review of its use in the management of hypertension.
    Plosker GL; Foster RH
    Drugs; 2000 Jul; 60(1):177-201. PubMed ID: 10929934
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study.
    Radaideh GA; Choueiry P; Ismail A; Eid E; Berrou JP; Sedefdjian A; Sévenier F; Pathak A
    Vasc Health Risk Manag; 2011; 7():491-5. PubMed ID: 21915165
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension.
    White WB; Anwar YA; Mansoor GA; Sica DA
    Am J Hypertens; 2001 Dec; 14(12):1248-55. PubMed ID: 11775134
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eprosartan does not affect the pharmacodynamics of warfarin.
    Kazierad DJ; Martin DE; Ilson B; Boike S; Zariffa N; Forrest A; Jorkasky DK
    J Clin Pharmacol; 1998 Jul; 38(7):649-53. PubMed ID: 9702851
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of eprosartan on the hemostatic system in patients with chronic kidney disease associated with hereditary thrombophilia].
    Kaliuzhin VV; Sibireva OF; Urazova OI; Tkalich LM; Zibnitskaia LI; Kaliuzhina EV; Sazonov ÉA; Grankina VIu
    Ter Arkh; 2013; 85(9):77-81. PubMed ID: 24261234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Eprosartan: a review of its use in the management of hypertension.
    Robins GW; Scott LJ
    Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interactions between sympathetic nervous system and endogenous endothelin in patients with essential hypertension.
    Bruno RM; Sudano I; Ghiadoni L; Masi L; Taddei S
    Hypertension; 2011 Jan; 57(1):79-84. PubMed ID: 21059990
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eprosartan dual action offers clinical benefit for elderly and overweight hypertensives.
    Cardiovasc J S Afr; 2004; 15(2):91-2. PubMed ID: 15148545
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmacology and clinical efficacy of angiotensin receptor blockers.
    Sica DA
    Am J Hypertens; 2001 Jul; 14(7 Pt 2):242S-247S. PubMed ID: 11459213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.